Project Grant R44AA027675

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This $399,891 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports the development and evaluation of the SMOKEMON wearable device and SMOKEDASH clinician software by Sensewhy, Inc. The project aims to assess the feasibility and clinical utility of using SMOKEMON to detect smoking topography and associated triggers among cancer survivors, with the goal of predicting and preventing smoking lapses during cessation...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $279,573 to the University of Houston System to develop and evaluate a novel, digitally-delivered olfactory method for reducing cigarette cravings and supporting smoking cessation. The key products and services to be delivered through this grant include: Refining the design and methodology for a first-generation Olfactory Stimulation Delivery System...

This STTR Phase I project grant from the National Center for Advancing Translational Sciences (NCATS) (CFDA 93.350) provides $649,264 to Grayrain, LLC to develop a novel platform for statistical obfuscation and de-identification of sensitive clinical data, including structured tabular data, text, and images. The goal is to enable secure data sharing and analytics while protecting patient privacy and personal health information. The technology proposed aims to produce de-identified synthetic data...

This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop new computational methods and workflows to improve the identification of tumor-associated antigens (TAAs) for the design of safer and more effective T-cell-based cancer immunotherapies. The $414,649 award will fund the integration of existing NCI resources, such as PVACtools, with new bioinformatics approaches for structural modeling and...

This Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $2,149,781 in funding to Rejuvenation Technologies Inc. (RTI) to develop advanced tools for the clinical translation of intravenously-infused RNA lipid nanoparticle (LNP) therapeutics. Specifically, the grant supports RTI's efforts to: Develop high-sensitivity analytical capabilities for their TERT mRNA LNP therapeutic drug product Conduct high-sensitivity...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, aims to develop a novel preclinical tool called the "Total Inhalable Deposition in an Actuated Lung" (TIDAL) model. The TIDAL model is designed to measure the spatial deposition of inhaled aerosol therapeutics and vaccines across the lung, accounting for factors such as patient-specific breathing patterns, anatomy, and disease state. The $427,811 award, valid from June...

This $650,450 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel TCR-engineered CD4+ T cell therapy for the treatment of lung cancer. The funded research project, led by the University of Southern California, aims to: Determine the mechanisms by which the proprietary "MIIC4 TCRM50A-STEM2 T cells" (or IMT-423) eliminate lung cancer cells. Produce GMP-grade master cell bank and viral...

This $304,971 Project Grant awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Medical Library Assistance (CFDA 93.879) program aims to develop an artificial intelligence (AI)-based tool for automating the extraction of data from tables in published studies. This capability will be integrated into Nested Knowledge's existing software platform, which provides an end-to-end workflow for conducting systematic literature reviews (SLRs) - a crucial process for...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $155,500 to The Washington University in St. Louis to accelerate the development of personalized, variant-specific therapies for ATP binding cassette transporter A3 (ABCA3) deficiency. The project will use human pulmonary epithelial cell lines, high-content analysis, and high-throughput screening of FDA-approved compounds to mechanistically classify and identify potential corrective...